Chimerix CEO and leadership

Mr. Sherman joined Chimerix in 2019 as Chief Executive Officer. Before joining the Company, he served as Chief Executive Officer of Endocyte and led it from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy. He joined the company in 2006 and as Chief Financial Officer and Chief Operating Officer and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. Mr. Sherman currently serves on the Board of Biospecifics Technologies, Inc, and as Chairman of the Board of Trustees for the Children’s Museum of Indianapolis. He also served on the Board of Directors at Mead Johnson Nutrition until the company’s acquisition by Reckitt Benckiser.

Joshua Allen is a Chief Technology Officer at CHIMERIX INC and is based in Philadelphia Y Alrededores, United States. He has worked as Sr VP:Research & Development at Oncoceutics Inc, Research Scientist at Penn State University, and Doctoral Researcher at LeeLee Parr. Joshua studied at Allegheny County between 2004 and 2008, University of Pennsylvania between 2008 and 2012, and North Carolina State Grange.

Randall Lanier is a Chief Science Officer at CHIMERIX INC and is based in North Carolina. He has worked as VP:Biology at CHIMERIX INC and Virologist at GSK. Randall attended New College between 1982 and 1986, University of Oxford, and University of Texas System.

Specialties: Medicinal chemistry, process chemistry, chemical outsourcing, compound sourcing, cGMP project management, CRO & CMO market space, pharmaceutical market analysis, process validation, API, API manufacturing, drug discovery, intellectual property, patents, vendor management, supply chain management, sourcing, nucleosides, ribosides, tropanes, epibatidines, organophosphorus chemistry, phosphate chemistry, phosphonate chemistry, phosphoramidate chemistry, amino alcohols, kinase inhibitors, oncology, naphthyridines, quinones, bicyclo compounds, xanthates, nitric oxide synthase, nitric oxide synthase inhibitors, nitric oxide, nitroxyl releasing agents, cocaine derivatives, hydroxylamines, N-phosphinoyl nitroso compounds, synthetic chemistry, biotechnology, process validation, chemical development, cGMP, cGMP manufacturing, HPAPI, vendor management, supply chain, secondary sourcing, global sourcing, outsourcing panel speaker, global manufacturing, raw material sourcing, raw material negotiations, drug discovery, hit to lead, lead optimization, candidate selection, early process development, chemical route scouting, process optimization, solid state chemistry, polymorphs, polymorphism, composition of matter

Mr. Sherman joined Chimerix in 2019 as Chief Executive Officer. Before joining the Company, he served as Chief Executive Officer of Endocyte and led it from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy. He joined the company in 2006 and as Chief Financial Officer and Chief Operating Officer and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. Mr. Sherman currently serves on the Board of Biospecifics Technologies, Inc, and as Chairman of the Board of Trustees for the Children’s Museum of Indianapolis. He also served on the Board of Directors at Mead Johnson Nutrition until the company’s acquisition by Reckitt Benckiser.